Evidence map›Paper›PMID 35201262›Full record

ArticleInvestigative ophthalmology & visual science2022

The Therapeutic Roles of Recombinant Hsp90α on Cornea Epithelial Injury.

Mingli Wang, Jialin Hu, Junwei Qu, Huili Huang, Jing Zhang, Jun Zhang, Hui Li, Xiukun Cui, Fengyan Zhang, Meng Yue Hu and 2 more

Open access · goldAbstract read
In one paragraph

Article in Investigative ophthalmology & visual science, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Mingli WangJoint National Laboratory for Antibody Drug Engineering, The First Affiliated Hospital of Henan University, Department of Cell Biology and Genetics, School of Basic Medical Science, Henan University, Kaifeng, China.
Jialin HuJoint National Laboratory for Antibody Drug Engineering, The First Affiliated Hospital of Henan University, Department of Cell Biology and Genetics, School of Basic Medical Science, Henan University, Kaifeng, China.
Junwei QuJoint National Laboratory for Antibody Drug Engineering, The First Affiliated Hospital of Henan University, Department of Cell Biology and Genetics, School of Basic Medical Science, Henan University, Kaifeng, China.
Huili HuangJoint National Laboratory for Antibody Drug Engineering, The First Affiliated Hospital of Henan University, Department of Cell Biology and Genetics, School of Basic Medical Science, Henan University, Kaifeng, China.
Jing ZhangJoint National Laboratory for Antibody Drug Engineering, The First Affiliated Hospital of Henan University, Department of Cell Biology and Genetics, School of Basic Medical Science, Henan University, Kaifeng, China.
Jun ZhangJoint National Laboratory for Antibody Drug Engineering, The First Affiliated Hospital of Henan University, Department of Cell Biology and Genetics, School of Basic Medical Science, Henan University, Kaifeng, China.
Hui LiJoint National Laboratory for Antibody Drug Engineering, The First Affiliated Hospital of Henan University, Department of Cell Biology and Genetics, School of Basic Medical Science, Henan University, Kaifeng, China.
Xiukun CuiJoint National Laboratory for Antibody Drug Engineering, The First Affiliated Hospital of Henan University, Department of Cell Biology and Genetics, School of Basic Medical Science, Henan University, Kaifeng, China.
Fengyan ZhangDepartment of Ophthalmology, First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Meng Yue HuJoint National Laboratory for Antibody Drug Engineering, The First Affiliated Hospital of Henan University, Department of Cell Biology and Genetics, School of Basic Medical Science, Henan University, Kaifeng, China.
Jing LiJoint National Laboratory for Antibody Drug Engineering, The First Affiliated Hospital of Henan University, Department of Cell Biology and Genetics, School of Basic Medical Science, Henan University, Kaifeng, China.
Yanzhong HuJoint National Laboratory for Antibody Drug Engineering, The First Affiliated Hospital of Henan University, Department of Cell Biology and Genetics, School of Basic Medical Science, Henan University, Kaifeng, China.
First Affiliated Hospital of Henan University · CNFirst Affiliated Hospital of Zhengzhou University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: The purpose of this study was to explore the therapeutic role of heat shock protein 90 (Hsp90) in wound healing of injury cornea epithelium. Methods: The right eye of C57BL/6N male mice were performed the debridement wounds in the center of the cornea using an algerbrush II blade. The injured area was determined by staining the cornea with fluorescein sodium and measured with image-J. Immunoblotting, ELISA and immunochemistry were used for determining protein expression. The quantitation PCR was performed to measure mRNA expression. Results: Hsp90α is upregulated at both the mRNA and protein levels, and is secreted extracellularly into the corneal stroma and tear film during the healing process after corneal injury in mice. This upregulation is associated with activation of HSF1. Administration of recombinant exogenous Hsp90α (eHsp90α) speeds up wound healing of injured corneal epithelium. The eHsp90α binds to low-density lipoprotein (LDL)-related protein-1 (LRP-1) on the corneal epithelial cells and increases phosphorylation of AKT at S473, which is associated with proliferation and migration corneal epithelial cells in vitro or vivo. Inhibition of AKT by its inhibitor LY294002 abolishes eHsp90α-induced migration and proliferation of corneal epithelial cells. Conclusion: Hsp90α is upregulated and secreted after corneal injury and acts to promote the healing process. Recombinant Hsp90α may be a promising therapeutic drug candidate for corneal injury.

Indexed as

AnimalsBlotting, WesternCell LineCell MovementCell ProliferationDebridementEnzyme-Linked Immunosorbent AssayEpithelium, CornealEye InjuriesGene Expression RegulationHeat Shock Transcription FactorsHSP90 Heat-Shock ProteinsHumansImmunohistochemistryLow Density Lipoprotein Receptor-Related Protein-1MaleHeat Shock Transcription FactorsHsf1 protein, mouseHSP90 Heat-Shock ProteinsHspca protein, mouseLow Density Lipoprotein Receptor-Related Protein-1Lrp1 protein, mouseProto-Oncogene Proteins c-aktRecombinant ProteinsRNA, Messenger

Identifiers

PMID35201262
PMCPMC8883155
OpenAlexW4213429614

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.